Trial Profile
Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics
- 28 Sep 2016 Planned number of patients changed from 14 to 18.
- 28 Sep 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 28 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.